Key result
DE-CMR identifies ~2-fold more cardiac sarcoidosis cases than standard clinical evaluation.
Why the study?
Sudden death is a leading cause of mortality in sarcoidosis patients and may represent unrecognized cardiac involvement, necessitating improved detection methods.
Does DE-CMR improve the detection of cardiac involvement compared to standard clinical evaluation in patients with extracardiac sarcoidosis?
Cohort (n=81)
Masked
Does DE-CMR improve the detection of cardiac involvement compared to standard clinical evaluation in patients with extracardiac sarcoidosis?
DE-CMR is significantly more sensitive than standard clinical consensus criteria for detecting cardiac involvement in patients with sarcoidosis and is associated with future adverse cardiovascular events.
Answers are grounded in this paper and cite their sources.
DE-CMR may detect more cardiac sarcoidosis than standard criteria; leaves open whether routine screening improves outcomes or warrants practice change.
BACKGROUND: In patients with sarcoidosis, sudden death is a leading cause of mortality, which may represent unrecognized cardiac involvement. Delayed-enhancement cardiovascular magnetic resonance (DE-CMR) can detect minute amounts of myocardial damage. We sought to compare DE-CMR with standard clinical evaluation for the identification of cardiac involvement. METHODS AND RESULTS: Eighty-one consecutive patients with biopsy-proven extracardiac sarcoidosis were prospectively recruited for a parallel and masked comparison of cardiac involvement between (1) DE-CMR and (2) standard clinical evaluation with the use of consensus criteria (modified Japanese Ministry of Health [JMH] guidelines). Standard evaluation included 12-lead ECG and at least 1 dedicated non-CMR cardiac study (echocardiography, radionuclide scintigraphy, or cardiac catheterization). Patients were followed for 21+/-8 months for major adverse events (death, defibrillator shock, or pacemaker requirement). Patients were predominantly middle-aged (46+/-11 years), female (62%), and black (73%) and had chronic sarcoidosis (median, 7 years) and preserved left ventricular ejection fraction (median, 56%). DE-CMR identified cardiac involvement in 21 patients (26%) and JMH criteria in 10 (12%, 8 overlapping), a >2-fold higher rate for DE-CMR (P=0.005). All patients with myocardial damage on DE-CMR had coronary disease excluded by x-ray angiography. Pathology evaluation in 15 patients (19%) identified 4 with cardiac sarcoidosis; all 4 were positive by DE-CMR, whereas 2 were JMH positive. On follow-up, 8 had adverse events, including 5 cardiac deaths. Patients with myocardial damage on DE-CMR had a 9-fold higher rate of adverse events and an 11.5-fold higher rate of cardiac death than patients without damage. CONCLUSIONS: In patients with sarcoidosis, DE-CMR is more than twice as sensitive for cardiac involvement as current consensus criteria. Myocardial damage detected by DE-CMR appears to be associated with future adverse events including cardiac death, but events were few, and this needs confirmation in a larger cohort.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2009) conducted a cohort in biopsy-proven extracardiac sarcoidosis (n=81). Delayed-enhancement cardiovascular magnetic resonance (DE-CMR) vs. Standard clinical evaluation (modified Japanese Ministry of Health [JMH] guidelines) was evaluated on identification of cardiac involvement (p=0.005). DE-CMR identified cardiac involvement in 26% of patients with extracardiac sarcoidosis compared to 12% identified by standard clinical evaluation (P=0.005).
Synapse has enriched 5 related papers. Consider them for comparative context: